## **1** Clinical characteristics of COVID-19 in children and

## 2 adolescents: a systematic review and meta-analysis

3	Name of the Authors:
4 5	Lixiang Lou <sup>1a</sup> , Hui Zhang <sup>1a</sup> , Baoming Tang <sup>2</sup> , Ming Li <sup>2</sup> , Zeqing Li <sup>2</sup> , Haifang Cao <sup>3</sup> , Jian Li <sup>4</sup> , Yuliang Chong <sup>5</sup> , Zhaowei Li <sup>2,*</sup>
6	Affiliation:
7	Lixiang Lou <sup>1</sup> : The Graduate School of Qinghai University, Xining, China
8	Email:loulixiang@qq.com
9	Hui Zhang <sup>1a</sup> : The Graduate School of Qinghai University, Xining, China
10	Email:zhanghui10157@163.com
11	Baoming Tang <sup>2</sup> : Department of Traumatology orthopedics, Affiliated Hospital of
12	Qinghai University, Xining, China
13	Email:18697126038@163.com
14	Ming Li <sup>2</sup> : Department of pediatric, Affiliated Hospital of Qinghai University, Xining,
15	China
16	Email:865880047@qq.com
17	Zeqing Li <sup>2</sup> : Department of Traumatology orthopedics, Affiliated Hospital of Qinghai
18	University, Xining, China
19	Email:lzq611206771@163.com
20	Haifang Cao <sup>3</sup> : Department of Liver Diseases, The Fourth People's Hospital of Qinghai
21	Province (Qinghai Specialized Hospital of Infectious Diseases), Xining,
22	China
23	Email:1736853849@qq.com
24	Jian Li <sup>4</sup> : The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
25	Email:543715871@qq.com
26	Yuliang Chong <sup>5</sup> : Affiliated Hospital of Yanbian University, Yanbian, China
27	Email:chongyuliang@163.com
28	*Corresponding Author: Zhaowei Li, Dr

- 29 Department of Traumatology orthopedics, Affiliated Hospital of Qinghai University,
- 30 Xining, China
- 31 Address:
- 32 29 Tongren Road, Xining, Qinghai, China
- 33 **Postal code:**810000
- 34 Zhaowei Li<sup>2,\*</sup> Email:Lzw6230@163.com
- 35 Phone : 86013709743526
- <sup>a</sup> These authors contributed equally to the manuscript.
- 37 **Competing interests:** No authors have competing interests in this research.
- **Funding:** This research did not receive any specific grant from funding agencies in
- 39 the public, commercial, or not-for-profit sectors.
- 40 Contributors: All the authors designed the study. LL, HZ, ZL and BT designed the
- 41 literature search and searched the articles. LL, HZ, ML, YC, JL, and BT contributed
- 42 to statistical analysis, interpretation of data and data review. LL, HZ wrote the first
- draft of the article. All the authors revised the article and approved the final version.

### 44 Summary

- 45 **Background:** Although the number of COVID-19 (coronavirus disease 2019) cases
- 46 continues to increase globally, there are few studies on the clinical characteristics of
- 47 children and adolescents with COVID-19.
- 48 **Objective:** To conduct a comprehensive systematic evaluation and meta-analysis of
- 49 the clinical characteristics of COVID-19 in children and adolescents to better guide
- 50 the response to the current epidemic.

Methods: We searched PubMed, Embase, the Cochrane Library, Web of Science, CNKI (Chinese database), Clinical Trials.gov and chictr.org.cn (China). The methodological quality of the included literature was evaluated using the Quality Assessment Tool for Case Series Studies. Meta-analysis was performed using STATA 14.0. Heterogeneity was assessed by the Q statistic and quantified using I<sup>2</sup>. We used fixed-effects or random-effects models to pool clinical data in the meta-analysis. Publication bias was evaluated by the Begg's test.

**Results:** We analyzed 49 studies involving 1627 patients. In the pooled data, the most

common clinical symptoms were fever (56% [0.50-0.61]) and cough (45% 59 60 [0.39–0.51]). The most common laboratory abnormalities were elevated procalcitonin (40% [0.23-0.57]), elevated lactate dehydrogenase (31% [0.19-0.43]), increased 61 62 lymphocyte count (28% [0.17-0.42]), increased creatine kinase (28% [0.18-0.40]), 63 and elevated C-reactive protein (26% [0.17–0.36]). The most common abnormalities determined by computed tomography were lower-lobe involvement (56% [0.42-64 0.70]), ground-glass opacities (33% [0.25–0.42]), bilateral pneumonia (32% [0.24-65 0.40]), patchy shadowing (31% [0.18- 0.45]), and upper lobe involvement (30% 66 [0.20-0.41]). 67 **Conclusion:** Disease severity among children and adolescents with COVID-19 was 68

milder than that among adult patients, with a greater proportion of mild and
asymptomatic cases, and thus, the diagnosis of COVID-19 and control of the infection
source are more challenging.

72 Keywords: COVID-19; 2019-nCoV; Child; Adolescent; review; meta-analysis.

## 73 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly 74 75 discovered coronavirus responsible for the coronavirus disease 2019 (COVID-19), 76 which was first reported in Wuhan City, Hubei Province in December 2019 [1]. On 77 January 12, 2020, the World Health Organization (WHO) officially named the novel 78 coronavirus "2019 novel coronavirus (2019-nCoV)" [2]. So far, over 20□ million 79 people live with COVID-19 worldwide, with 750,000 deaths, and the death toll is still 80 rising. Currently, COVID-19 outbreaks are continuing to spread across the globe. 81 SARS-CoV-2 is spread by between-human transmission via droplets or close contact [3], but there are also studies showing that it can be transmitted from person to person 82 by aerosols [4]. Fecal-oral routes may also constitute a potential person-to-person 83 transmission route. Several studies have reported that the virus may still be 84 85 transmitted from COVID-19-positive stool samples even after COVID-19 with 86 negative detection of viral ribonucleic acid from nasopharyngeal swabs [5,13]. The

87 development of the immune system in children and adolescents is not yet perfect, and 88 it is easy for various types of viruses to cause infections. COVID-19 is a novel infectious disease. The population lacks immunity and is generally susceptible in 89 90 crowded conditions. However, a study has found that COVID-19 in children below 91 the age of 10 years constituted only 0.35% of cases [6]. It is essential to identify and control patients who are suspected of having COVID-19 as early as possible and to 92 prevent the further spread of the epidemic by controlling the source of infection and 93 cutting off transmission pathways. Although the number of COVID-19 cases 94 95 continues to grow globally, there are few studies focusing on the clinical manifestations, laboratory tests, chest imaging examinations, and complications for 96 97 children and adolescents with COVID-19. We conducted a systematic review and 98 meta-analysis of the clinical characteristics of children and adolescents to describe 99 comprehensive characteristics of COVID-19 in children and adolescents to better treat 100 and control the current outbreak.

## **101 1** Methods

#### 102 **1.1 Retrieval of published studies**

103 PRISMA and MOOSE guidelines were used to conduct this systematic 104 review and meta-analysis [7-8]. We used the Medical Subject Heading (MeSH) terms 105 and corresponding keywords to develop the search strategy. The search terms included: "Child (MeSH)" or "children" or "Adolescent (MeSH)" or "Teens" and 106 107 "COVID-19 (MeSH)" or "SARS-CoV-2 infection" and "clinical characteristics" or 108 "clinical features". We searched PubMed, Embase, the Cochrane Library, Web of Science, and CNKI (Chinese database). We also searched Clinical Trials.gov and 109 110 chictr.org.cn (China) to find unpublished studies. There were no restrictions on use, including no language restrictions. The search time limit was from the establishment 111 112 of each database to July 10, 2020. To ensure comprehensiveness of the search strategy, 113 the search tasks were performed independently by two researchers (LL, BT). Details

114 of the search strategy are provided as shown in Supplementary Text S1.

#### 115 **1.2 Inclusion and exclusion criteria**

#### 116 **1.2.1 Inclusion criteria**

117 □ Research type: Not limited by research type or research design. □ Research object:
118 Participants included children and adolescents between the ages of 1 and 18 years,
119 cases with positive nucleic acid tests in patients with COVID-19. □ Intervention was
120 unrestricted. □Outcomes included clinical manifestations, laboratory examinations,
121 and CT examinations.

#### 122 **1.2.2 Exclusion criteria**

Infants less than 1 year of age. □ Fewer than 4 cases reported. □ Surveillance
reports, community outbreaks, review papers, commentary articles, conference papers,
duplicated reports, reports for which the full text cannot be obtained. □ There is no
definite measure or laboratory marker for the diagnosis of COVID-19. □ The
outcome was not clear.

#### 128 **1.3 Data extraction**

Two researchers (HZ, LL) independently screened and cross-checked the 129 130 literature regarding the inclusion and exclusion criteria. Any disagreement was 131 resolved by discussion between the two reviewers. A customized form was used to 132 record the first author, publication time, design of the trial, country, the number of 133 COVID-19 patients, ages, sexes, durations between onset of symptoms and 134 hospitalization (days), times of patient examinations, diagnostic criteria for 135 COVID-19, clinical symptoms, laboratory outcomes, chest CT findings, and 136 supportive treatment. In addition, we screened them according to whether blood or 137 respiratory samples were positive by real-time polymerase chain reaction tests for 138 SARS-CoV-2 nucleic acid.

#### 139 **1.4 Quality assessment of included meta-analyses**

5

For the case series study, we used the Quality Assessment Tool for Case Series Studies to evaluate article suitability for systematic review [9]. Each item was scored as either 0 or 1 point based on the scoring criteria, and scores were summed across items to generate an overall quality score ranging from 0 to 9. Overall scores were classified as low risk (≥7 points), moderate risk (5–6 points), or high risk (0–4 points). Two evaluators (HZ, LL) separately performed quality assessment. Any disagreements were resolved through discussion among the investigators.

#### 147 **1.5 Statistical analysis**

148 Meta-analysis was performed using STATA 14.0. A random-effects model was 149 used to compute the combined prevalence and 95% confidence intervals (CI). We 150 calculated the pooled incidence of clinical symptoms, laboratory findings, and chest CT findings. Heterogeneity was assessed using Cochran's Q test with a significance 151 level of p < 0.1 and quantified using the I<sup>2</sup> statistic. Heterogeneity was quantified 152 using the I-squared  $(I^2)$  statistic and categorized as low  $(I^2 < 25\%)$ , moderate  $(I^2)$ 153 =25-50%) or high  $(l^2 > 50\%)$ . A model of fixed effect (FE) was set with 95% CI if no 154 statistical evidence of heterogeneity existed ( $p \ge 0.1$ ,  $I^2 \le 50\%$ ), while a model of 155 156 random effect (RE) was applied to estimate pooled effect with 95% confidence intervals (CI) if statistical heterogeneity was found (p < 0.1,  $I^2 > 50\%$ ). If significant 157 heterogeneity (p < 0.1,  $I^2 > 75\%$ ) was detected, we used sensitivity analysis to explore 158 159 its possible sources. A random-effects model was used if the reason for heterogeneity 160 could not be identified. Publication bias was detected using Begg's test. Probability (p)161 values less than 0.05 were considered statistically significant.

### 162 **2 Results**

#### **2.1 Systematic search results**

164 The search strategy initially identified 467 publications, including 60 from

165 PubMed, 131 from Embase, 5 from Cochrane, and 196 from Web of Science. Search 166 results from different sources were entered into an EndNote library, from which 146 167 duplicates and 366 irrelevant studies were removed. Among the remaining 101 168 articles selected for full-text reading, 52 studies were removed. Finally, 49 studies 169 [10-58] were included in the meta-analysis involving 1627 participants. Only three of 170 49 included studies reported critically ill patients [15,26,31]. These critically ill 171 patients were not excluded from the meta-analysis. Mechanical ventilation analysis 172 included only critically ill patients. We extracted data based on different outcome 173 indicators and then conducted a single-arm meta-analysis. Figure 1 illustrates the 174 detailed process of the literature review.

#### 175 **2.2 Study characteristics**

176 The characteristics of the studies are displayed in Table 1. The studies included 177 were published between February 26, 2020 and June 29, 2020. Fifty articles including 178 41 (84%) English papers and 8 (16%) Chinese papers were included in our study, and 179 all were journal articles. Patients were from six countries: 41 from China, 4 from the 180 United States, 1 from Italy, 1 from France, 1 from Turkey, and 1 from Iran. All 181 included studies were retrospective studies; one was a case-control study, and the 182 remainder were retrospective case series. The number of patients enrolled in each 183 study ranged from 4 to 157, and patients' ages ranged from 1 to 18 years. Male 184 patients accounted for 53%, and female patients accounted for 47%. All patients were 185 confirmed to be positive for SARS-CoV-2 nucleic acid by respiratory or blood 186 sample.

#### 187 **2.3 Methodological assessment of the included literature**

For the evidence of effectiveness meta-analysis, we used the Quality Assessment Tool for Case Series Studies to evaluate article suitability for the systematic review. Among the 49 studies included, 43 studies were rated as low risk of bias, 6 studies as moderate, and none were rated as high risk of bias (Table 2).

#### 192 **2.4 Meta-analysis results**

193 We meta-analyzed the prevalence of 18 clinically relevant symptoms (Table 3), 194 the prevalence of 12 laboratory outcomes (Table 4), and the prevalence of 9 chest CT 195 findings (Table 5). The analysis of the 48 articles included showed that boys (53% 196 [0.50–0.56]) had a higher prevalence of COVID-19 than did girls (47% [0.44–0.50]). Among the 18 frequently reported clinical symptoms (Table 3), the incidence of 197 198 clinical symptoms of COVID-19 in children and adolescents was 86% [95% CI 199 0.77-0.93], and the most common clinical symptoms were fever (56% [0.50-0.61]) 200 (Supplementary Figs S 1), cough (45% [0.39–0.51]) (Supplementary Figs S 2), 201 sneezing (14% [0.08–0.22]), and vomiting (14% [0.06–0.24]). Other symptoms included diarrhea (12% [0.06–0.19]), anhelation (11% [0.04–0.19]), sore throat (10% 202 203 [0.05-0.16]), headache (10% [0.04-0.17]), fatigue (9% [0.05 -0.15]), myalgia (8% 204 [0.02–0.17]), increased sputum volume (7% [0.03–0.13]), and abdominal pain (6% 205 [0.01–0.12]). In addition, the meta-analysis included 3 studies with critically ill 206 children and showed that the incidence of mechanical ventilation in severely ill 207 children was 38% [0.27–0.50]. All the above results were statistically significant 208 ( $p \square < \square 0.05$ ). There was no statistical significance (P>0.05) for the analyzed results 209 for renal insufficiency or mortality. Of the 49 included studies, only 3 case studies of 210 critically ill children reported deaths, and no deaths were reported in the remaining 47 211 studies. Publication bias was found for symptoms of sore throat, anhelation, headache, 212 diarrhea, and vomiting, and no publication bias was found for the remaining clinical 213 symptoms.

Among the 13 frequently reported laboratory findings (Table 4), the most common abnormalities in laboratory examinations were elevated procalcitonin (40% [0.23–0.57]), elevated lactate dehydrogenase (31% [0.19–0.43]), increased lymphocyte count (28% [0.17–0.42]), increased creatine kinase (28%[0.18–0.40]), and elevated C-reactive protein (26% [0.17–0.36]) (Supplementary Figs S 3, 4, 5, 6 and 7). Additional laboratory findings included elevated AST (24%[ 0.09–0.43]), decreased leukocyte count (21% [0.13–0.29]), elevated D-dimer (19% [0.09–0.31]),

reduced lymphocyte count (15% [0.09–0.21]), increased leukocyte count (15% [0.07–0.25]), and elevated ALT (7% [0.05–0.10]). Because only two studies reported elevated creatinine, we did not perform a meta-analysis. All the results described above were statistically significant ( $p\Box < \Box 0.05$ ). Begg's test indicated significant publication bias for decreased leukocyte count, elevated ALT, and elevated D-dimers, and no remaining laboratory findings showed significant publication bias at p < 0.05.

227 Among the 9 frequently reported chest CT findings (Table 5), in the included 26 studies, the prevalence of chest CT examinations showing infection was 67% 228 [0.58-0.76] (Supplementary Figs S 8). The most common abnormalities from chest 229 230 CT examination were lower lobe involvement (56% [0.42-0.70]), ground-glass 231 opacities (33% [0.25–0.42]), bilateral pneumonia (32% [0.24-0.40]), patchy shadows 232 (31% [0.18-0.45]), and upper lobe involvement (30% [0.20-0.41]) (Supplementary 233 Figs S 9, 10, 11, 12 and 13). Other outcomes included unilateral pneumonia (26% 234 [0.22-0.30]), tubercles (13% [0.06-0.21]), pleural fluid (3% [0.00-0.08]). All the 235 abovementioned results were statistically significant ( $p \square < \square 0.05$ ). Publication bias 236 was found for bilateral pneumonia, and there was no evidence of significant 237 publication bias among the remaining 9 included studies.

## 238 **3 Discussion**

This meta-analysis summarizes the latest and most comprehensive study for 239 240 clinical characteristics of COVID-19 in children and adolescents, from the first report 241 of COVID-19 to July 10, 2020, including clinical features, laboratory outcomes, and 242 chest CT findings. We conducted a systematic review and meta-analysis of 49 studies 243 involving 1627 patients. The proportion of boys was significantly higher than that of girls, also consistent with previous studies, according to the synthesis results of our 244 meta-analysis. Compared with the two previous systematic reviews on this topic, we 245 246 have included more studies and analyzed 40 results in detail.

The main clinical features in children and adolescents with COVID-19 were fever (56%), cough (45%), sneezing (14%), vomiting (14%), and other less common

249 results included diarrhea (12%), anhelation (11%), sore throat (10%), headache (10%), 250 fatigue (9%), myalgia (8%), increased sputum volume (7%), and abdominal pain (6%). 251 According to a previous study of COVID-19 in adult patients, the main clinical 252 features of COVID-19 were fever, cough, and fatigue [59-60]. In this study of children and adolescents, patients with symptoms of sneezing and vomiting also 253 accounted for reasonably large percentages. Previous studies have found that nasal 254 255 congestion, runny nose and diarrhea were less common in children than in adults 256 [61-63]. Critical or fatal pediatric COVID-19 cases were rare, and children with 257 COVID-19 showed less severe clinical symptoms than did adults. In addition, one 258 study showed that children may be less likely to be infected, and may show milder 259 symptoms if they are infected [63]. Therefore, children and adolescents are more 260 likely to have potential hidden infections, which should attract the attention of 261 clinicians and parents of children.

262 The most common laboratory abnormalities were elevated procalcitonin 263 (40%), elevated lactate dehydrogenase (31%), increased lymphocyte count (28%), 264 elevated creatine kinase (28%) and elevated C-reactive protein (26%). These 265 laboratory abnormalities indicate clear viral infection. Previous studies have found the 266 most common laboratory test abnormalities in adult patients to be elevated C-reactive 267 protein and reduced lymphocyte count [59-60]. All these abnormal laboratory markers 268 are nonspecific, so their clinical applications are limited. According to the findings of 269 our study, the elevated procalcitonin, elevated lactate dehydrogenase and increased 270 lymphocyte count may appear as nonspecific markers in children and adolescents. 271 Previous research has suggested that mortality, acute respiratory distress syndrome 272 (ARDS), headache, increased leukocyte count, and elevated lactate dehydrogenase are 273 significantly higher in studies with a larger proportion of older patients [59]. When 274 evaluating suspicious cases, doctors cannot rely on these laboratory abnormalities to 275 rule out or confirm the diagnosis of COVID-19 [59]. One study suggested that these 276 abnormalities may be related to the cytokine storm caused by infection [64]. Recently, 277 another study revealed that COVID-19 might mainly affect T lymphocytes, especially 278 CD4+T cells, resulting in significant lymphopenia [65]. The results of this study

279 showed that the prevalence of increased lymphocyte count in children (28%) was 280 higher than the prevalence of decreased lymphocyte count (15%), which may be 281 related to the percentage of lymphocytes elevated in the growth and development of 282 the child's immune system. In terms of liver enzymes, elevated AST (24%) was more 283 common than elevated ALT (7%), which indicates that liver function may be damaged 284 to varying degrees. In addition, reduced leukocyte count (21%) was more common 285 than increased leukocyte count (15%). Of the 49 studies reviewed, only two reported 286 elevated creatinine. Therefore, elevated creatinine was extremely rare among children with COVID-19. 287

Chest CT examination was one of the important auxiliary examinations for 288 289 COVID-19 pneumonia, and it has a very satisfactory effectiveness for the 290 examination of lung lesions. Previous research has found that most patients have mild 291 symptoms and elevated body temperature, but pulmonary lesions are relatively 292 obvious. Li [66] found that chest CT had a low rate of missed diagnosis of COVID-19 293 (3.9%) and could thus be used as a rapid diagnostic method for this disease to 294 optimize patient management. However, CT is still limited in identifying specific 295 viruses and distinguishing viruses. Our meta-analysis showed that the prevalence of 296 children and adolescents with COVID-19 chest CT examinations showing infection 297 was 67%. A recent study of 62 adult patients with COVID-19 showed that 52 (83.9%) 298 had an abnormal chest CT scan, which was much higher than the frequency in 299 children and adolescents with an abnormal chest CT scan, consistent with previous 300 reports [67]. The results of our meta-analysis showed that the prevalence of 301 ground-glass opacity and patchy shadows were 33% and 31%, respectively. Lung 302 lesions of patients with COVID-19 showed imageology findings similar to those of 303 other viral pneumonia, mainly ground-glass opacities and patchy shadows. The most 304 common position for lesions detected by CT scan was in the lower lobe (56%), while 305 incidence of upper lobe lesion was 30%. Bilateral pneumonia (32%) was more 306 common than unilateral pneumonia (26%). A study of adult COVID-19 patients 307 showed that bilateral pneumonia was present in 73.2% of cases, indicating that adults 308 are more likely to experience bilateral lung infection than are children and adolescents

309 [59]. The results of this study found that tubercles (13%) and pleural fluid (3%) rarely
310 occur in children and adolescents with COVID-19. Chang et al. found that, compared
311 with SARS, COVID-19 has prominent characteristics in children, and the typical
312 appearance of chest CT is ground-glass opacity, which is also consistent with our
313 study [68]. Other CT findings, such as air bronchogram and lymphadenopathy, are
314 less common [69].

Among the 49 articles included, only 3 studies of critically ill children reported deaths. Among the 1627 patients included, only 7 deaths occurred, and the overall mortality was lower than the reported adult mortality (3.6%) [59]. Compared with other common viral diseases, the number of cases of COVID-19 in children and adolescents is small, and the mortality is low, which is very gratifying.

320 There are also several limitations to our systematic review and meta-analysis. 321 First, all reported cases were retrospective studies, and there was a high degree of 322 heterogeneity among the results of the study. Because there were many studies 323 included, it is difficult to avoid heterogeneity. No subgroup analysis was performed 324 on different age groups of the included children and adolescents. Second, the current 325 COVID-19 pandemic has not been effectively controlled. Our study was analyzed 326 during the COVID-19 outbreak. Most of the included patients were from China, and 327 there may be certain geographical and ethnic differences. Subgroup analysis was not 328 performed, which may also bias the results of the analysis.

## **4 Conclusion**

This meta-analysis provides a comprehensive review of the clinical characteristics of COVID-19 in children and adolescents. The main clinical features of children and adolescents were fever and cough. The most frequently reported laboratory abnormalities were elevated procalcitonin, elevated lactate dehydrogenase, increased lymphocyte count, increased creatine kinase, and elevated C-reactive protein. From chest computed tomography, the most common lesion site was the lower lobe. Bilateral pneumonia was more common than unilateral pneumonia, and

- the main manifestations were ground-glass opacities and patchy shadowing. The
- condition of children and adolescents with COVID-19 was milder than that of adult
- 339 patients, with a greater proportion of asymptomatic and mild cases, and specific
- 340 diagnosis and source-of-infection control were more challenging.
- 341

#### 342 **Declarations**

#### 343 Ethics approval and consent to participate

- Not applicable. This article does not contain any studies with human participants
- 345 performed by any of the authors.

#### **346 Consent for publication**

- 347 All participating authors provide consent for publication.
- 348 Availability of data and materials
- All data generated or analyzed during this study are included in this article.

#### 350 Competing interests

351 The authors declare that they have no competing interests.

#### 352 Funding

353 The authors state that this work has not received financial support.

#### 354 Authors' contributions

- 355 All the authors designed the study. LL, HZ, ZL and BT designed the literature search
- and searched the articles. LL, HZ, ML, YC, JL, and BT contributed to statistical
- analysis, interpretation of data and data review. LL and HZ wrote the first draft of the
- article. All the authors revised the article and approved the final version.

#### 359 Acknowledgements

360 Not applicable.

## 361 **References**

362 [1] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global
363 health concern. Lancet. 2020;395(10223):470–473. doi:
364 10.1016/S0140-6736(20)30185-9.

365 [2] World Health Organization.Clinica Imanagement of severe acute respiratory

novelcoronavirus(nCoV)

infection

when

infection

366

when

issuspected:interimguidance,25January2020[R].WHO,2020. 367 [3] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, 368 369 Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry 370 depends on ACE2 and TMPRSS2 and is blocked by a clinically proven 371 proteaseinhibitor. Cell. 2020 Mar 5. [4] van Doremalen, Neeltje, Trenton Bushmaker, Dylan H. Morris, Myndi G. 372 Holbrook, Amandine Gamble, Brandi N. Williamson, Azaibi Tamin et al. "Aerosol and 373 surfacestability of SARS-CoV-2 as compared with SARS-CoV-1." New England 374 375 Journal of Medicine (2020). [5] Xu, Yi, Xufang Li, Bing Zhu, Huiying Liang, Chunxiao Fang, Yu Gong, Qiaozhi 376 Guo et al. "Characteristics of pediatric SARS-CoV-2 infection and potential evidence 377 378 for persistent fecal shedding." 379 viral Nature Medicine (2020): 380 1-4.doi:10.1038/s41591-020-0817-4. [6] YangY LQ, LiuM, et al. Epidemiological and clinical features of the 2019 novel 381 coronavirus outbreak in China. medRxiv preprint 2020 382 383 [7] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting 384 systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. Published 2009 Jul 21. 385 386 doi:10.1136/bmj.b2700 [8] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in 387 epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in 388 Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. 389 390 doi:10.1001/jama.283.15.2008 391 [9] American National Institute of Health. https://www.nhlbi.nih.gov/health-topics/ 392 study-quality-assessment-tools. [10] Mohammadi A, Mohebbi I, Khademvatani K, et al. Clinical and radiological 393 characteristics of pediatric patients with COVID-19: focus on imaging findings 394 395 [published online ahead of print, 2020 Jun 13]. Jpn J Radiol. 2020;1-6. 396 doi:10.1007/s11604-020-01003-6 [11] Tang A, Xu W, Chen P, et al. A retrospective study of the clinical characteristics 397 in infection 26 children[J]. medRxiv, 2020. 398 of COVID-19 doi: 399 10.1101/2020.03.08.20029710 [12] Li B, Shen J, Li L, Yu C. Radiographic and Clinical Features of Children With 400 Coronavirus Disease (COVID-19) Pneumonia. Indian Pediatr. 2020;57(5):423-426. 401 402 doi:10.1007/s13312-020-1816-8 403 [13] Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus 404 infection: clinical and epidemiological features [published online ahead of print, 2020] 405 Feb 28]. Clin Infect Dis. 2020;ciaa198. doi:10.1093/cid/ciaa198 406 [14] Foster CE, Moulton EA, Munoz FM, et al. Coronavirus Disease 2019 in Children 407 Cared for at Texas Children's Hospital: Initial Clinical Characteristics and 408 Outcomes. J Pediatric Infect Dis Soc. 2020;9(3):373-377. doi:10.1093/jpids/piaa072 409 [15] Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with 14

410 coronavirus disease 2019 in Wuhan: a single center's observational study. World J A11 Dedictr 2020;16(2):251,250, doi:10.1007/s12510.020.00254.4

- 411 Pediatr. 2020;16(3):251-259. doi:10.1007/s12519-020-00354-4
- 412 [16] Feng K, Yun Y X, Wang X F, et al. Analysis of CT features of 15 children with
- 413 2019 novel coronavirus infection. Zhonghua er ke za zhi= Chinese journal of
- 414 pediatrics, 2020, 58: E007-E007. doi: 10.3760/cma.j.cn112140-20200210-00071
- 415 [17] Ma H, Hu J, Tian J, et al. A single-center, retrospective study of COVID-19
- 416 features in children: a descriptive investigation. BMC Med. 2020;18(1):123.
  417 Published 2020 May 6. doi:10.1186/s12916-020-01596-9
- 418 [18] Mannheim J, Gretsch S, Layden JE, Fricchione MJ. Characteristics of
- 419 Hospitalized Pediatric COVID-19 Cases Chicago, Illinois, March April 2020
- 420 [published online ahead of print, 2020 Jun 1]. J Pediatric Infect Dis Soc. 2020;piaa070.
  421 doi:10.1093/jpids/piaa070
- 422 [19] Lan L, Xu D, Xia C, Wang S, Yu M, Xu H. Early CT Findings of Coronavirus
- 423 Disease 2019 (COVID-19) in Asymptomatic Children: A Single-Center Experience.
- 424 Korean J Radiol. 2020;21(7):919-924. doi:10.3348/kjr.2020.0231
- 425 [20] Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of
- 426 children with coronavirus disease 2019. Pediatr Pulmonol. 2020;55(6):1430-1432.
  427 doi:10.1002/ppul.24767
- 428 [21] Liu YJ, Chen P, Liu ZS, et al. Clinical features of asymptomatic or subclinical
- 429 COVID-19 in children. Chinese Journal of Contemporary Pediatrics, 2020, 22(6): 578.
  430 doi:10.7499/j.issn.1008-8830.2004088(in chinese)
- 431 [22] Ma H, Shao J, Wang Y, et al. High resolution CT features of COVID-19 in 432 children. Chinese Journal of Radiology (China), 2020, 54(4) : 310-313. doi: 433 10.2760/cmg i gn112140.20200206.00100
- 433 10.3760/cma.j.cn112149-20200206-00100
- 434 [23] Ma YL, Xia SY, Wang M, et al. Clinical features of children with SARS-CoV-2
- 435 infection: an analysis of 115 cases. Chinese Journal of Contemporary Pediatrics, 2020,
  436 22(4): 290-293. doi:10.7499/j.issn.1008-8830.2003016(in chinese)
- 437 [24] Liu M, Song Z, Xiao K. High-Resolution Computed Tomography Manifestations
- 438 of 5 Pediatric Patients With 2019 Novel Coronavirus. J Comput Assist Tomogr.
  439 2020;44(3):311-313. doi:10.1097/RCT.00000000001023
- 440 [25] Korkmaz MF, Türe E, Dorum BA, Kılıç ZB. The Epidemiological and Clinical
- 441 Characteristics of 81 Children with COVID-19 in a Pandemic Hospital in Turkey: an
- 442 Observational Cohort Study. J Korean Med Sci. 2020;35(25):e236. Published 2020
- 443 Jun 29. doi:10.3346/jkms.2020.35.e236
- [26] Oualha M, Bendavid M, Berteloot L, et al. Severe and fatal forms of COVID-19
  in children. Arch Pediatr. 2020;27(5):235-238. doi:10.1016/j.arcped.2020.05.010
- 446 [27] Parri N, Magistà AM, Marchetti F, et al. Characteristic of COVID-19 infection in
- 447 pediatric patients: early findings from two Italian Pediatric Research Networks. Eur J
- 448 Pediatr. 2020;179(8):1315-1323. doi:10.1007/s00431-020-03683-8
- [28] Peng H, Gao P, Xu Q, et al. Coronavirus disease 2019 in children: Characteristics,
- 450 antimicrobial treatment, and outcomes. J Clin Virol. 2020;128:104425.
  451 doi:10.1016/j.jcv.2020.104425
- 452 [29] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological
- 453 features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China:

454 an observational cohort study. Lancet Infect Dis. 2020;20(6):689-696.
455 doi:10.1016/S1473-3099(20)30198-5

456 [30] Steinberger S, Lin B, Bernheim A, et al. CT Features of Coronavirus Disease

457 (COVID-19) in 30 Pediatric Patients [published online ahead of print, 2020 May

458 22]. AJR Am J Roentgenol. 2020;1-9. doi:10.2214/AJR.20.23145

459 [31] Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes460 of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US

461 and Canadian Pediatric Intensive Care Units [published online ahead of print, 2020

462 May 11]. JAMA Pediatr. 2020;10.1001/jamapediatrics.2020.1948.
463 doi:10.1001/jamapediatrics.2020.1948

464 [32] Shen Q, Guo W, Guo T, et al. Novel coronavirus infection in children outside of

465 Wuhan, China. Pediatr Pulmonol. 2020;55(6):1424-1429. doi:10.1002/ppul.24762

466 [33] Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus
467 disease cases between children and their families in China - the character of children
468 with COVID-19. Emerg Microbes Infect. 2020;9(1):707-713.
469 doi:10.1080/22221751.2020.1744483

[34] Tan X, Huang J, Zhao F, et al. Clinical features of children with SARS-CoV-2
infection: an analysis of 13 cases from Changsha, China. Zhongguo dang dai er ke za
zhi= Chinese journal of contemporary pediatrics, 2020, 22(4): 294.

473 doi:10.7499/j.issn.1008-8830.2003199

474 [35] Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical
475 characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J
476 Clin Virol. 2020;127:104353. doi:10.1016/j.jcv.2020.104353

477 [36] Waltuch T, Gill P, Zinns LE, et al. Features of COVID-19 post-infectious
478 cytokine release syndrome in children presenting to the emergency department
479 [published online ahead of print, 2020 May 23]. Am J Emerg Med.
480 2020;S0735-6757(20)30403-4. doi:10.1016/j.ajem.2020.05.058

[37] Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children
compared with adults in Shandong Province, China. Infection. 2020;48(3):445-452.
doi:10.1007/s15010-020-01427-2

[38] Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical features of pediatric
patients with coronavirus disease (COVID-19). J Clin Virol. 2020;127:104377.
doi:10.1016/j.jcv.2020.104377

[39] Wu H, Zhu H, Yuan C, et al. Clinical and Immune Features of Hospitalized
Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
JAMA Netw Open. 2020;3(6):e2010895. Published 2020 Jun 1.
doi:10.1001/jamanetworkopen.2020.10895

[40] Wu Q, Xing Y, Shi L, et al. Coinfection and Other Clinical Characteristics of
COVID-19 in Children. Pediatrics. 2020;146(1):e20200961.
doi:10.1542/peds.2020-0961

494 [41] Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric

495 patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol.

496 2020;55(5):1169-1174. doi:10.1002/ppul.24718

497 [42] Xu H, Liu E, Xie J, et al. A follow-up study of children infected with

498 SARS-CoV-2 from western China. Ann Transl Med. 2020;8(10):623.
499 doi:10.21037/atm-20-3192

500 [43] Xu H, Liu E, Xie J, et al. A follow-up study of children infected with
501 SARS-CoV-2 from western China. Ann Transl Med. 2020;8(10):623.
502 doi:10.21037/atm-20-3192

[44] Lu Y, Wen H, Rong D, Zhou Z, Liu H. Clinical characteristics and radiological
features of children infected with the 2019 novel coronavirus. Clin Radiol.
2020;75(7):520-525. doi:10.1016/j.crad.2020.04.010

[45] Han YN, Feng ZW, Sun LN, et al. A comparative-descriptive analysis of clinical
characteristics in 2019-coronavirus-infected children and adults [published online
ahead of print, 2020 Apr 6]. J Med Virol. 2020;10.1002/jmv.25835.
doi:10.1002/jmv.25835

510 [46] Li Y, Cao J, Zhang X, Liu G, Wu X, Wu B. Chest CT imaging characteristics of
511 COVID-19 pneumonia in preschool children: a retrospective study. BMC Pediatr.
512 2020;20(1):227. Published 2020 May 18. doi:10.1186/s12887-020-02140-7

- 513 [47] Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with
  514 Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275-280.
  515 doi:10.1007/s11596-020-2172-6
- [48] Zheng G, Wang B, Zhang H, et al. Clinical characteristics of acute respiratory
  syndrome with SARS-CoV-2 infection in children in South China [published online
  ahead of print, 2020 Jun 24]. Pediatr Pulmonol. 2020;10.1002/ppul.24921.
  doi:10.1002/ppul.24921

[49] Zhong Z, Xie X, Huang W, et al. Chest CT findings and clinical features of
coronavirus disease 2019 in children. Journal of Central South University(Medical
sciences). 2020;45(3):236-242. doi:10.11817/j.issn.1672-7347.2020.200206 (in
chinese)

- 524 [50] Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of
  525 children with coronavirus disease 2019. Pediatr Pulmonol. 2020;55(6):1430-1432.
  526 doi:10.1002/ppul.24767
- 527[51] Huang XP, Xie SH, Jiang LL, et al. Analysis of clinical characteristics and528imaging characteristics of COVID-19 in children in Gannan region. Journal of529GannanMedicalUniversity.2020,40(03):239-242.
- 530 doi:10.3969/j.issn.1001-5779.2020.03.005(in chinese)
- 531 [52] Wu HP, Li BF, Chen X, et al. Clinical features of coronavirus disease 2019 in
- children aged <18 years in Jiangxi, China: an analysis of 23 cases. Chinese Journal of
- 533ContemporaryPediatrics.2020,22(05):419-424.doi:53410.7499/j.issn.1008-8830.2003202(in chinese)doi:
- [53] Li Q, Peng X, Sun Z, et al. Clinical and imaging characteristics of children with
  corona virus disease 2019 (COVID-19). Radiol Practice, 2020, 35: 277-80.
  doi:10.13609/j.cnki.1000-0313.2020.03.007
- 538 [54] Liu J, Luo W, Deng Z, et al. Clinical and epidemiological characteristics of 91
- children conformed with COVID-19. Chin J Nosocomiol, 2020, 30: 1645-9.
  doi:10.11816/cn.ni.2020-200550
- 541 [55] Wang KJ, Xu L, Yin Hui, et al. Clinical and CT Imaging Findings of Novel

542 Coronavirus Pneumonia Children. Journal of Hubei University in of 543 Medicine.2020,39(02):134-138. doi:10.13819/j.issn.2096-708X.2020.02.007(in 544 chinese) 545 [56] Yang L, Li Z, Xu H, et al. Epidemiological and clinical characteristics of 10 546 children with coronavirus disease (COVID-19) in Jinan City. Journal of Shandong 547 University(Health Sciences).2020,58(04):36-39. doi:10.6040/j.issn.1671-7554.0.2020.305(in chinese) 548 [57] Yin H, Wu HY, Chen J, et al. Clinical characteristics and bedside lung ultrasound 549 550 findings of family-clustered pediatric COVID-19. Guangxi Medical 551 Journal.2020,42(10):1281-1284. doi:10.11675/j.issn.0253-4304.2020.10.22(in 552 chinese) 553 [58] Zhang XG, Ma Y, Xiao JA, et al. Clinical characteristics of novel coronavirus pneumonia in children in Jinan. Journal of Shandong University(Health 554 555 Sciences).2020,58(03):62-64. doi:10.6040/j.issn.1671-7554.0.2020.180(in chinese) 556 [59] Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 557 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 558 2020;80(6):656-665. doi:10.1016/j.jinf.2020.03.041 [60] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, 559 560 discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-583. 561 doi:10.1002/jmv.25757 [61] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 562 563 novel coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497-506. 564 [62] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive 565 study.Lancet. 2020. 395(10223): 507-513. 566 [63] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of 567 568 Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020. [64] Chen L, Liu H G, Liu W, et al. Analysis of clinical features of 29 patients with 569 570 2019 novel coronavirus pneumonia[J]. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 2020, 571 572 43: E005-E005. 573 [65] Chen G., Wu D., Guo W., et al. Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019.2020:medRxiv2020.02.16.20023903. 574 575 [66] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in 576 Diagnosis and Management. AJR Am J Roentgenol. 2020;214(6):1280-1286. 577 doi:10.2214/AJR.20.22954 [67] Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 578 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgenol. 579 580 2020;214(6):1287-1294. doi:10.2214/AJR.20.22975 581 [68] Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. J Formos Med Assoc. 582 583 2020;119(5):982-989. doi:10.1016/j.jfma.2020.04.007 584 [69] Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of 585 the COVID-19 pneumonia: Focus on pregnant women and children. J Infect.

586 2020;80(5):e7-e13. doi:10.1016/j.jinf.2020.03.007

#### 588 Tables

#### 589 Table 1 Characteristics of studies included in the meta-analysis.

Authors	Types	Country	No. of	Sex (% male)	Age (years), median (IQR) OR mean + SD	Duration between	Check	1	Primary outcom	e
	studies (RCS/C CS)		cubes	() ( maile)	OR range	and hospitalization (median; mean ± SD [range], days)	putent and	Clinical Symptoms	Laboratory outcomes	Chest CT findings
Afshin et al. <sup>[10]</sup>	RCS	Iran	27	37.0%	4.7±4.16Y	NA	DH	А	NA	А
Tang et al. <sup>[11]</sup>	RCS	China	26	34.6%	6.9±0.7Y	13.6±1.03	DH	А	А	А
Li B et al. <sup>[12]</sup>	RCS	China	22	54.5%	8±6Y	NA	DH	А	NA	А
Cai et al. <sup>[13]</sup>	RCS	China	10	40.0%	mean6.1Y;3-131M	NA	DH	А	А	NA
Catherine et al. <sup>[14]</sup>	RCS	America	57	56.1%	median10.7Y;0.1-20.2Y	NA	DH	А	NA	NA
Sun et al. <sup>[15]</sup>	RCS	China	8	75.0%	2 M-15Y	NA	DH	А	А	А
Feng et al. <sup>[16]</sup>	RCS	China	15	33.3%	4-14Y	NA	DH	А	А	А
Ma et al. [17]	RCS	China	76	55.3%	NA	NA	DH	А	А	А
Jonathan et al. <sup>[18]</sup>	RCS	America	64	43.8%	0-17Y	mean 4	DH	А	NA	NA
Lan et al. <sup>[19]</sup>	RCS	China	4	50.0%	9.8±3.2Y;7-13y	7-15	DH	А	А	А
Li et al. <sup>[20]</sup>	RCS	China	10	50.0%	9.2±4.6Y	NA	DH	А	А	А
Liu Y et al. <sup>[21]</sup>	RCS	China	53	64.2%	8±4Y	10±4	DH	NA	А	NA
Ma H et al. <sup>[22]</sup>	RCS	China	22	54.5%	median 4Y;2 M-14Y	7-17	DH	А	А	А
Ma YL et al. <sup>[23]</sup>	RCS	China	115	63.5%	51d-15Y	NA	DH	А	А	А

Authors	Types	Country	No. of	Sex	Age (years), median (IQR)	Duration between	Check	P	rimary outcom	e
	studies (RCS/C CS)		Cases	(70 marc)	OR mean ± 55	and hospitalization (median; mean ± SD [range], days)	patient unie	Clinical Symptoms	Laboratory outcomes	Chest CT findings
Liu M Q et al. <sup>[24]</sup>	RCS	China	4	100.0%	7.4±4.6Y	NA	DH	А	NA	NA
Muhammet et al. <sup>[25]</sup>	RCS	Turkey	81	59.3%	mean 9.5Y;3.2-15.1Y	median 5;4-10	DH	А	А	А
Oualha et al. <sup>[26]</sup>	RCS	France	27	37.0%	1 M-18Y	median 6; 2-35	DH	А	А	А
Parri Niccolò et al. <sup>[27]</sup>	RCS	Italy	130	56.2%	0–17Y	NA	DH	А	А	А
Hui et al. <sup>[28]</sup>	RCS	China	75	58.7%	6.1±4.8Y	NA	DH	А	А	А
Qiu et al. <sup>[29]</sup>	RCS	China	36	63.9%	8.3±3.5Y	mean 14	DH	А	А	А
Sharon et al. <sup>[30]</sup>	RCS	China	30	50.0%	median10Y; 6-15Y	NA	DH	А	А	А
ShekerdemianLS et al. <sup>[31]</sup>	RCS	America	45	52.1%	mean13Y;4.2-16.6Y	median 7;4-13	DH	А	NA	NA
Shen et al. <sup>[32]</sup>	RCS	China	9	33.3%	7.6 ±3.8Y	NA	DH	А	А	А
Su et al. <sup>[33]</sup>	RCS	China	9	33.3%	4.1 ±2.9Y	NA	DH	А	А	А
Tan X et al. <sup>[34]</sup>	RCS	China	13	30.8%	7.8±5.2Y	NA	DH	А	А	А
Tan Y P et al. <sup>[35]</sup>	RCS	China	10	30.0%	7(1-12)Y	NA	DH	А	А	А
Temima et al. <sup>[36]</sup>	RCS	America	4	75.0%	10±3.6Y	NA	DH	А	А	27
Du et al. <sup>[37]</sup>	CCS	China	14	42.9%	mean6.2Y; 0-16Y	NA	DH	А	А	А
Song et al. <sup>[38]</sup>	RCS	China	16	62.5%	median8.5y;11.5 M-14Y	NA	DH	А	А	А

Authors	Types Country No. of Sex Age (years), median (Io		Age (years), median (IQR)	Duration between	Check	Primary outcome				
	of studies (RCS/C CS)		cases	(% male)	OR mean ± SD OR range	onset of symptoms and hospitalization (median; mean ± SD [range], days)	patient time	Clinical Symptoms	Laboratory outcomes	Chest CT findings
Wu H et al. <sup>[39]</sup>	RCS	China	157	43.9%	median7Y;1.5-10.6Y	NA	DH	А	А	А
Wu Q et al. <sup>[40]</sup>	RCS	China	74	59.5%	mean6.0Y; 0.1-15.1Y	NA	DH	А	NA	А
Xia et al. <sup>[41]</sup>	RCS	China	20	65.0%	1 M-6Y	mean 2.9;8-20	DH	А	А	А
Xu HG et al. <sup>[42]</sup>	RCS	China	32	53.1%	8.7±4.7Y	NA	DH	А	NA	А
Xu Y et al. <sup>[43]</sup>	RCS	China	9	NA	7.2±5.5Y	NA	DH	А	А	А
Lu et al. <sup>[44]</sup>	RCS	China	9	55.6%	7.8±5.3Y	NA	DH	А	А	А
Han et al. <sup>[45]</sup>	RCS	China	7	57.1%	mean1.3Y; 0.2-13Y	NA	DH	А	А	А
Li Y et al. <sup>[46]</sup>	RCS	China	8	37.5%	2.6±1.4Y	NA	DH	А	А	А
Zheng F et al. <sup>[47]</sup>	RCS	China	25	56.0%	median3Y ( 2–9Y)	NA	DH	А	NA	А
Zheng G et al. <sup>[48]</sup>	RCS	China	52	53.8%	median9Y ( 4-12Y )	mean14.5;10-17	DH	А	NA	NA
Zhong Z et al. <sup>[49]</sup>	RCS	China	8	NA	7.3±3.9Y	NA	DH	А	А	А
Zhu L et al. <sup>[50]</sup>	RCS	China	10	50.0%	9.2±4.6Y	NA	DH	А	А	А
Huang et al. <sup>[51]</sup>	RCS	China	5	60.0%	10±6.6Y	NA	DH	А	А	А
Wu et al. <sup>[52]</sup>	RCS	China	23	39.1%	3 M-17Y	7-24	DH	А	А	А
Li Q et al. <sup>[53]</sup>	RCS	China	30	60.0%	Median6Y	NA	DH	А	NA	А

Authors	Types	Country	No. of	Sex	Age (years), median (IQR)	Duration between	Check	Primary outcome		
	of		cases	(% male)	OR mean ± SD	onset of symptoms	patient time			
	studies				OR range	and hospitalization		Clinical	Laboratory	Chest CT
	(RCS/C					(median; mean $\pm$ SD		Symptoms	outcomes	findings
	CS)					[range], days)				
Liu J et al. <sup>[54]</sup>	RCS	China	91	61.5%	median 4Y	NA	DH	А	А	А
Wang et al. <sup>[55]</sup>	RCS	China	20	30.0%	median2Y and 9M	NA	DH	А	А	А
Liu Y et al. <sup>[56]</sup>	RCS	China	10	30.0%	5.1±4.1Y	median 15	DH	А	NA	NA
Yin et al. <sup>[57]</sup>	RCS	China	15	26.7%	median 2Y and 8M	NA	DH	А	А	NA
Zang et al. <sup>[58]</sup>	RCS	China	10	30.0%	median 4 Y;mean 4.9Y	NA	DH	А	А	А

EVER: interquartile; RCS = Retrospective case series; CCS = Case-control study; D= day; M= month; Y= years; DH= During hospitalization; A= Available; NA = Not

591 available.

592

#### 593 Table 2 Quality Assessment Tool for Case Series Studies.

Author			NIH Quali	ity Assessı	ment Tool	for Case S	Series Stuc	lies		Quality (Total
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Quality Score)
Afshin et al. <sup>[10]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Tang et al. <sup>[11]</sup>	1	1	1	NA	1	0	1	1	1	Good (7)
Li B et al. <sup>[12]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Cai et al. <sup>[13]</sup>	1	1	1	NA	1	0	1	1	1	Good (7)
Catherine et al. <sup>[14]</sup>	1	0	1	NA	1	1	1	1	1	Good (7)
Sun et al. <sup>[15]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)

Author	Quality (Total									
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Quality Score)
Feng et al. <sup>[16]</sup>	1	0	1	NA	NR	0	1	1	1	Fair (5)
Ma et al. <sup>[17]</sup>	1	0	1	NA	NR	0	1	1	1	Fair (5)
Jonathan et al. <sup>[18]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Lan et al. <sup>[19]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Li et al. <sup>[20]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Liu Y et al. <sup>[21]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Ma H et al. <sup>[22]</sup>	1	1	1	NA	0	1	1	1	1	Good (7)
Ma Y L et al. <sup>[23]</sup>	1	1	0	NA	NR	0	1	1	1	Fair (5)
Liu M Q et al. <sup>[24]</sup>	1	1	NR	NA	NR	1	1	1	1	Fair (6)
Muhammet et al. <sup>[25]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Oualha et al. <sup>[26]</sup>	1	1	1	NA	1	0	1	1	1	Good (7)
Parri Niccolò et al. [27]	1	1	1	NA	1	0	1	1	1	Good (7)
Hui et al. <sup>[28]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Qiu et al. <sup>[29]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Sharon et al. <sup>[30]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
ShekerdemianLS et al. <sup>[31]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Shen et al. <sup>[32]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)

Author	NIH Quality Assessment Tool for Case Series Studies									
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Quality Score)
Su et al. <sup>[33]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Tan X et al. <sup>[34]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Tan Y P et al. <sup>[35]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Temima et al. <sup>[36]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Du et al. <sup>[37]</sup>	1	1	1	1	NR	1	1	1	1	Good (8)
Song et al. <sup>[38]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Wu H et al. <sup>[39]</sup>	1	1	1	NA	NR	0	1	1	1	Fair (6)
Wu Q et al. <sup>[40]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Xia et al. <sup>[41]</sup>	1	0	1	NA	0	1	1	1	1	Fair (6)
Xu HG et al. <sup>[42]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Xu Y et al. <sup>[43]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Lu et al. <sup>[44]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Han et al. <sup>[45]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Li Y et al. <sup>[46]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Zheng F et al. <sup>[47]</sup>	1	0	1	NA	1	1	1	1	1	Good (7)
Zheng G et al. <sup>[48]</sup>	1	0	1	NA	1	1	1	1	1	Good (7)
Zhong Z et al. <sup>[49]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Zhu L et al. <sup>[50]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)

Author			NIH Quali	ty Assessi	ment Tool	for Case S	Series Stuc	lies		Quality (Total
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Quality Score)
Huang et al. <sup>[51]</sup>	1	1	1	NA	NR	1	1	1	1	Good (7)
Wu et al. <sup>[52]</sup>	1	1	1	NA	1	0	1	1	1	Good (7)
Li Q et al. <sup>[53]</sup>	1	0	1	NA	1	1	1	1	1	Good (7)
Liu J et al. <sup>[54]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Wang et al. <sup>[55]</sup>	1	0	1	NA	1	1	1	1	1	Good (7)
Liu Y et al. <sup>[56]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Yin et al. <sup>[57]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)
Zang et al. <sup>[58]</sup>	1	1	1	NA	1	1	1	1	1	Good (8)

594 Good: Met 7–9 criteria, Fair: Met 4–6 criteria, Poor: Met 0–3 criteria. NA = not applicable, NIH = National Institutes of Health, NR = not reported, Q1: Was study 595 question or objective clearly stated?, Q2: Was study population clearly and fully described, including case definition?, Q3: Were cases consecutive?, Q4: Were 596 subjects comparable?, Q5: Was intervention clearly described?, Q6: Were outcome measures clearly defined, valid, reliable, and implemented consistently across 597 all study participants?, Q7: Was length of follow-up adequate?, Q8: Were statistical methods well-described?, Q9: Were results well-described?.

598

#### 599 Table 3 Clinical Symptoms

Outcomes	No.	No.	I^2	Q test	Fixed	Random	95% Conf.	Test of	Test of	Begg's Test
	includ-ed	events/total		P=	pooled	pooled	Interval	Z=	P=	P=
	studies									
With clinical symptoms	35	796/984	90.67%	0.00	NA	0.86	0.77–0.93	18.71	0.00	0.158
Fever	44	729/1404	72.68%	0.00	NA	0.56	0.50-0.61	25.06	0.00	0.418
Cough	43	664/1393	71.36%	0.00	NA	0.45	0.39-0.51	21.90	0.00	0.509

Outcomes	No.	No.	I^2	Q test	Fixed	Random	95% Conf.	Test of	Test of	Begg's Test
	includ-ed	events/total		P=	pooled	pooled	Interval	Z=	P=	P=
	studies									
Sneezing	13	111/627	80.58%	0.00	NA	0.14	0.08-0.22	6.13	0.00	0.669
Sore throat	19	85/759	76.67%	0.00	NA	0.10	0.05-0.16	5.84	0.00	0.039
Increased sputum volume	5	12/146	0.00%	0.58	0.07	NA	0.03-0.13	4.81	0.00	0.806
Anhelation	14	70/607	84.96%	0.00	NA	0.11	0.04-0.19	4.55	0.00	0.037
Myalgia	8	38/347	76.06%	0.00	NA	0.08	0.02-0.17	3.36	0.00	0.386
Fatigue	15	99/755	75.04%	0.00	NA	0.09	0.05-0.15	5.75	0.00	0.586
Headache	14	71/654	80.61%	0.00	NA	0.10	0.04-0.17	4.79	0.00	0.042
Abdominal Pain	7	17/244	53.45%	0.04	NA	0.06	0.01-0.12	3.08	0.00	0.133
Diarrhea	24	142/1100	87.06%	0.00	NA	0.12	0.06-0.19	5.91	0.00	0.001
Vomiting	18	120/693	88.08%	0.00	NA	0.14	0.06-0.24	4.86	0.00	0.010
Renalinsufficiency	3	6/178	71.29%	0.03	NA	0.03	0.00-0.11	1.89	0.06	0.296
Mechanical ventilation	3	30/78	0.00%	0.96	0.38	NA	0.27-0.50	9.62	0.00	0.296
Death	49	7/1627	0.00%	0.98	0.00	NA	0.00-0.00	0.00	1.00	0.000
Percentage of boys	47	852/1613	31.37%	0.02	0.53	NA	0.50-0.56	41.17	0.00	0.229
Proportion of girls	47	761/1613	31.37%	0.02	0.47	NA	0.44-0.50	38.86	0.00	0.229
Table 4 Laboratory	outcomes									
Outcomes	No.includ-	No.	I^2	Q test	Fixed	Random	95% Conf.	Test of	Test of	Begg's Test
	ed studies	events/total		P=	pooled	pooled	Interval	Z=	P=	P=
Leukocytes ↑	14	37/335	70.45%	0.00	NA	0.15	0.07-0.25	4.92	0.00	0.024

Outcomes	No.includ-	No.	I^2	Q test	Fixed	Random	95% Conf.	Test of	Test of	Begg's Test
	ed studies	events/total		P=	pooled	pooled	Interval	Z=	P=	P=
Leukocytes↓	24	135/645	78.23%	0.00	NA	0.21	0.13-0.29	8.02	0.00	0.196
lymphocyte个	19	126/454	84.64%	0.00	NA	0.28	0.17-0.42	6.67	0.00	0.276
lymp hocyte ↓	19	88/554	66.42%	0.00	NA	0.15	0.09-0.21	7.47	0.00	0.674
ALT↑	13	45/448	39.76%	0.07	0.07	NA	0.05-0.10	6.11	0.00	0.032
AST↑	7	47/242	78.83%	0.00	NA	0.24	0.09–0.43	4.27	0.00	0.095
Creatinine个	2	4/121	NA	NA	NA	NA	NA	NA	NA	NA
Creatine Kinase个	13	108/444	77.70%	0.00	NA	0.28	0.18-0.40	7.88	0.00	0.271
Lactate dehydrogenase个	13	121/468	80.93%	0.00	NA	0.31	0.19–0.43	7.47	0.00	0.299
C reactive protein $\uparrow$	21	196/710	84.45%	0.00	NA	0.26	0.17–0.36	8.33	0.00	0.880
D - dimer↑	9	35/234	68.53%	0.00	NA	0.19	0.09-0.31	5.06	0.00	0.022
Procalcitonin个	13	195/495	91.14%	0.00	NA	0.40	0.23-0.57	6.58	0.00	0.951
ALT: Alanine aminot	transferase; AS	ST: Aspartate amino	otransferase.							
Table 5 Chest CT findin	gs									
Outcomes	No.	No.	I^2	Q test	Fixed	Random	95% Conf.	Test of	Test of	Begg's Test
	includ-ed studies	events/total		P=	pooled	pooled	Interval	Z=	P=	Ρ=
CT showed infection	25	386/574	78.19%	0.00	NA	0.67	0.58–0.76	17.32	0.00	0.453
Bilateral pneumonia	20	191/694	74.19%	0.00	NA	0.32	0.24-0.40	11.80	0.00	0.019

Outcomes	No. includ-ed studies	No. events/total	I^2	Q test P=	Fixed pooled	Random pooled	95% Conf. Interval	Test of Z=	Test of P=	Begg's Test P=
Unilateral pneumonia	16	151/552	32.92%	0.10	0.26	NA	0.22-0.30	14.62	0.00	0.892
Involvement in upper lobe	9	81/237	60.59%	0.01	NA	0.30	0.20-0.41	8.79	0.00	0.208
Involvement in lower lobe	10	150/262	77.52%	0.00	NA	0.56	0.42-0.70	10.56	0.00	0.857
Patchy shadowing	5	69/195	67.69%	0.01	NA	0.31	0.18-0.45	6.92	0.00	0.221
Ground-glass opacities	27	311/970	84.44%	0.00	NA	0.33	0.25-0.42	11.50	0.00	0.217
Pleural fluid	3	6/218	56.13%	0.10	NA	0.03	0.00-0.08	2.18	0.03	0.296
Tubercles	4	13/93	33.52%	0.21	0.13	NA	0.06-0.21	4.64	0.00	0.089

604 CT: Computed Tomography.

#### 605 Figures



30

#### 617

## **Figure S 1** Forest plots of the prevalence of fever among children and adolescents with COVID-19.

618





31

629 630

Study

Anjue Tang BO LI Cai Jiehao

Parri Niccolò

ShenQinxue

Xu Hongmei Y. Lu

Ya?nan Han

Xianping Huang Huaping Wu

Xiaoguo Zang Overall (I^2 = 71.36%, p = 0.00)

0

yang li Zheng F Zheng G Zhong Z Zhu L

Qian Li

Jie Liu Kejun Wang Liu Yang Hui Yin

-.5

Su Liang

Tan X Tan Y P

Wu H XiaW

Peng Hui Qiu Haiyan Sharon Steinberger

Temima Waltuch Wenjun Du Wenliang Song

Feng K

Afshin Mohammadi

Catherine E. Foster Dan Sun

Huijing Ma Jonathan Mannheim Li Zhu

Ma H Ma, Y. L Menggi Liu Muhammet Furkan Korkmaz

#### **Figure S 2** Forest plots of the prevalence of cough among children and adolescents with COVID-19.

ES (95% CI)

0.85 (0.66, 0.96)

0.65 (0.38, 0.86)

0.59 (0.36, 0.79)

0.63 (0.24, 0.91)

0.60 (0.46, 0.72) 0.67 (0.22, 0.96)

0.07 (0.00, 0.32)

0.54 (0.42, 0.65)

0.75 (0.63, 0.85)

0.30 (0.07, 0.65)

0.23 (0.08, 0.45)

0.41 (0.32, 0.50)

0.25 (0.01, 0.81)

0.52 (0.40, 0.63)

0.42 (0.33, 0.51)

0.61 (0.49, 0.72)

0.19 (0.08, 0.36)

0.27 (0.12, 0.46)

0.11 (0.00, 0.48)

0.11 (0.00, 0.48) 0.46 (0.19, 0.75)

0.30 (0.07, 0.65) 0.50 (0.07, 0.93)

0.21 (0.05, 0.51)

0.38 (0.15, 0.65)

0.45 (0.36, 0.53)

0.65 (0.41, 0.85)

0.38 (0.21, 0.56)

0.33 (0.07, 0.70)

0.71 (0.29, 0.96)

0.88 (0.47, 1.00)

0.44 (0.24, 0.65)

0.48 (0.34, 0.62)

0.63 (0.24, 0.91)

0.30 (0.07, 0.65) 0.60 (0.15, 0.95)

0.48 (0.27, 0.69) 0.67 (0.47, 0.83)

0.56 (0.45, 0.66)

0.35 (0.15, 0.59)

0.10 (0.00, 0.45) 0.33 (0.12, 0.62)

0.10 (0.00, 0.45)

0.45 (0.39, 0.51)

1

Weight

2.67

2.26

2.50

1.56

3.20 1.32

2.14

3.36

3.27

1.76

2.50

3.53

1.02

3.39

3.57

3.35

2.90

2.76

1.67

1.67

2.01

1.76

1.02

2.08

2.20

3.61

2.41

2.81

1.67

1.44

1.56

2.61

3.15

1.56

1.76

1.18

2.53

2.76

3.44

2.41 1.76

2.14

1.76

100.00

1.5



- 631
- 632
- 633
- 634
- 635
- 636
- 637
- 638
- 639
- 640

.5

# Figure S 3 Forest plots of the prevalence of elevated procalcitonin among childrenand adolescents with COVID-19.

	Study	ES (95% CI)	% Weight
	Li Zhu	0.00 (0.00, 0.31)	7.11
	Liu Y	0.34 (0.22, 0.48)	8.84
	Muhammet Furkan Korkm <del>aa –</del>	0.04 (0.01, 0.10)	9.02
	Oualha	0.59 (0.33, 0.82)	7.88
	Qiu Haiyan	0.17 (0.06, 0.33)	8.60
	Temima Waltuch	• 1.00 (0.40, 1.00)	5.37
	Wenjun Du	0.36 (0.13, 0.65)	7.62
	Wu H	0.47 (0.39, 0.56)	9.19
	XiaW	• 0.80 (0.56, 0.94)	8.07
	Xu Y	- 0.44 (0.14, 0.79)	6.93
	Ya?nan Han	0.43 (0.10, 0.82)	6.48
	Xianping Huang	0.40 (0.05, 0.85)	5.82
	Jie Liu	0.59 (0.49, 0.70)	9.06
	Overall (I^2 = 91.14%, p = 0.00)	0.40 (0.23, 0.57)	100.00
	-5 0 5	1	1.5
643			
C 1 4			
644			
645			
646			
040			
647			
648			
649			
049			
650			
651			
652			
653			
654			
655			
656			
000			
657			
658			

## 659 660

# **Figure S 4** Forest plots of the prevalence of elevated lactate dehydrogenase among children and adolescents with COVID-19.

	Study	ES (95% CI)	% Weight
	Anjue Tang	0.46 (0.27, 0.67)	8.92
	Cai Jiehao 🔹	0.25 (0.03, 0.65)	6.06
	Liu Y 🚽	0.04 (0.00, 0.13)	10.05
	Muhammet Furkan Korkmaz 🛛 🔳	0.17 (0.10, 0.27)	10.50
	ShenQinxue	0.11 (0.00, 0.48)	6.37
	Temima Waltuch	• 1.00 (0.40, 1.00)	4.27
	Wenjun Du	0.50 (0.23, 0.77)	7.53
	Wu H -	0.22 (0.15, 0.29)	10.92
	Xu Y	0.11 (0.00, 0.48)	6.37
	Ya?nan Han	0.29 (0.04, 0.71)	5.70
	Zhong Z	0.50 (0.16, 0.84)	6.06
	Jie Liu	0.36 (0.26, 0.47)	10.60
	Xiaoguo Zang	0.70 (0.35, 0.93)	6.66
	Overall (I^2 = 80.93%, p = 0.00)	0.31 (0.19, 0.43)	100.00
	-5 0 5	1	1
663 664 665			
665			
00/			
668			
668 669			
668 669 670			
668 669 670 671			
668 669 670 671 672			
668 669 670 671 672 673			
<ul> <li>668</li> <li>669</li> <li>670</li> <li>671</li> <li>672</li> <li>673</li> <li>674</li> <li>675</li> </ul>			

#### 677

## Figure S 5 Forest plots of the prevalence of increased lymphocyte count among

678

children and adolescents with COVID-19.



## Figure S 6 Forest plots of the prevalence of increased creatine kinase among childrenand adolescents with COVID-19.



## **Figure S 7** Forest plots of the prevalence of C-reactive protein among children and

#### 713 adolescents with COVID-19.



## **Figure S 8** Forest plots of the prevalence of chest CT examinations showing infection

#### among children and adolescents with COVID-19.

	Study	ES (95% CI)	% Weight
-	Afshin Mohammad	i 0.67 (0.46, 0.83)	4.56
	Aniue Tang	0.69 (0.48, 0.86)	4.53
	Feng K	0.60 (0.32, 0.84)	3.98
	Huijing Ma	0.91 (0.82, 0.96)	5.18
	Lan Lan	0.75 (0.19, 0.99)	2.33
	Li Zhu	0.50 (0.19, 0.81)	3.50
	Ma H	0.86 (0.65, 0.97)	4.38
	Oualha	0.88 (0.62, 0.98)	4.06
	Peng Hui	0.71 (0.59, 0.81)	5.18
	Sharon Steinberge	r 0.23 (0.10, 0.42)	4.65
	ShenQinxue -	0.22 (0.03, 0.60)	3.37
	Su Liang	0.44 (0.14, 0.79)	3.37
	Tan X	0.46 (0.19, 0.75)	3.82
	Wenliang Song	0.69 (0.41, 0.89)	4.06
	WuQ	0.50 (0.38, 0.62)	5.17
	Xu Hongmei	0.81 (0.64, 0.93)	4.70
	Xu Y	0.78 (0.40, 0.97)	3.37
	Y. Lu	0.56 (0.21, 0.86)	3.37
	Ya?nan Han	0.71 (0.29, 0.96)	3.04
	Zheng F	0.68 (0.46, 0.85)	4.50
	Zhong Z	0.63 (0.24, 0.91)	3.22
	Zhu L	0.50 (0.19, 0.81)	3.50
	Huaping Wu	0.55 (0.32, 0.76)	4.38
	Kejun Wang	1.00 (0.83, 1.00)	4.29
	Xiaoguo Zang		3.50
_			100.00
4	5 0	.5 1	1.5

# Figure S 9 Forest plots of the prevalence of lower lobe involvement among children and adolescents with COVID-19.

	Church .			%
	Study		ES (95% CI)	Weight
	Afshin Mohammadi		0.44 (0.25, 0.65)	10.80
	BOLI		0.68 (0.45, 0.86)	10.32
	Feng K		0.27 (0.08, 0.55)	9.28
	Huijing Ma		0.62 (0.50, 0.73)	12.48
	Lan Lan	•	0.75 (0.19, 0.99)	5.20
	Ma H		0.73 (0.50, 0.89)	10.32
	Sharon Steinberger		0.33 (0.17, 0.53)	11.03
	Wenliang Song		0.19 (0.04, 0.46)	9.47
	Qian Li		0.77 (0.58, 0.90)	11.03
	Kejun Wang		- 0.85 (0.62, 0.97)	10.07
	Overall (I^2 = 77.52%, p = 0.00)	$\langle \rangle$	0.56 (0.42, 0.70)	100.00
-5	0	5	1	1

### 752 753

# **Figure S 10** Forest plots of the prevalence of ground-glass opacities among children and adolescents with COVID-19.

	Study	ES (95% CI)	% Weight
	Afshin Mohammadi	0.30 (0.14, 0.50)	3.97
	BO LI	0.30 (0.17, 0.39)	3.01
	Huijing Ma	0.66 (0.54, 0.76)	4 52
	lanlan	• 1.00 (0.40, 1.00)	2.01
	MaH	0.45 (0.24, 0.68)	3.81
	Ma, Y, L	0.43 (0.33, 0.52)	4.64
	Muhammet Furkan Kor <del>kmaz</del>	0.10 (0.02, 0.27)	4.04
	Peng Hui	0.07 (0.02, 0.15)	4.52
	Qiu Haiyan	0.53 (0.35, 0.70)	4.16
	Sharon Steinberger	0.20 (0.08, 0.39)	4.04
	ShenQinxue	0.22 (0.03, 0.60)	2.92
	Su Liang	0.11 (0.00, 0.48)	2.92
	Tan X Tan X	0.15 (0.02, 0.45)	3.31
	Tan Y P	0.50 (0.19, 0.81)	3.03
	Wenliang Song	0.44 (0.20, 0.70)	3.52
	Wu H	0.34 (0.27, 0.43)	4.70
	Wu Q -	0.12 (0.06, 0.22)	4.51
	XiaW	0.60 (0.36, 0.81)	3.73
	Xu Hongmei 🛛 👘 🖳	0.25 (0.11, 0.43)	4.09
	Xu Y	0.44 (0.14, 0.79)	2.92
	Y.Lu	0.44 (0.14, 0.79)	2.92
	Xianping Huang	0.40 (0.05, 0.85)	2.25
	Huaping Wu	0.39 (0.20, 0.61)	3.84
	Qian Li	0.13 (0.04, 0.31)	4.04
	Jie Liu —	0.12 (0.06, 0.21)	4.58
	Kejun Wang	0.55 (0.32, 0.77)	3.73
	Overall $(1^2 = 84.44\%, p = 0.00)$	0.33 (0.25, 0.42)	100.00
	5 0 .5	1	1.5
/54			
755			
756			
756			
756			
756 757			
756 757			
756 757			
756 757 758			
756 757 758			
756 757 758 759			
756 757 758 759			
756 757 758 759			
756 757 758 759 760			
756 757 758 759 760			
756 757 758 759 760 761			
756 757 758 759 760 761			
756 757 758 759 760 761			
756 757 758 759 760 761 762			
756 757 758 759 760 761 762			
756 757 758 759 760 761 762 763			
756 757 758 759 760 761 762 763			

### 764 765

## **Figure S 11** Forest plots of the prevalence of bilateral pneumonia among children and adolescents with COVID-19.



# Figure S 12 Forest plots of the prevalence of patchy shadows among children andadolescents with COVID-19.



## Figure S 13 Forest plots of the prevalence of upper lobe involvement among childrenand adolescents with COVID-19.

